Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 41Leukemia 34Lymphoma 22Myelodysplastic Syndromes 16Hodgkin Disease 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 9Leukemia, Myeloid, Acute 9Recurrence 8Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Chronic-Phase 7Anemia, Aplastic 7Waldenstrom Macroglobulinemia 6Lymphoma, T-Cell, Peripheral 6Congenital Abnormalities 6Burkitt Lymphoma 6Sezary Syndrome 5Primary Myelofibrosis 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Large-Cell, Immunoblastic 5Graft vs Host Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell, Cutaneous 4

Interventions

Cyclophosphamide 10ofatumumab 8fludarabine 6Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3obinutuzumab 3ibrutinib 3acalabrutinib 3Melphalan 3pirtobrutinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × Alemtuzumab × Clear all
NCT00230282 2014-10-06

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Stanford University

Phase 2 Completed
25 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00292760 2009-12-16

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

Royal Marsden NHS Foundation Trust

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡